It has been about a month since the last earnings report for Halozyme Therapeutics (HALO) . Shares have added about 14.8% in that time frame, outperforming the S&P 500. Will the recent positive trend continue leading up to its next earnings release, or is Halozyme Therapeutics due for a pullback? Before we dive into how investors and analysts have reacted as of late, let's take a quick look at the most recent earnings report in order to get a better handle on the important drivers. Halozyme's Q2 Earnings & ...

Taking full advantage of the stock market and investing with confidence are common goals for new and old investors, and Zacks Premium offers many different ways to do both. The popular research service can help you become a smarter, more self-assured investor, giving you access to daily updates of the Zacks Rank and Zacks Industry Rank, the Zacks #1 Rank List, Equity Research reports, and Premium stock screens. Zacks Premium includes access to the Zacks Style Scores as well. What are the Zacks Style Scores? ...

SAN DIEGO, Aug. 28, 2024 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme") today announced that Dr. Helen Torley, President and Chief Executive Officer, and Tram Bui, VP of Investor Relations and Corporate Communications, are scheduled to present and host investor meetings at the following investor conferences. Details of the presentations are as follow: Event: 2024 Wells Fargo Healthcare Conference Format: Fireside Chat and 1x1 Meetings Presentation Date: Wednesday, September 4, 2024 ...

FX Empire Logo English check-icon Italiano Español Português Deutsch العربية Français Important DisclaimersThe content provided on the website includes general news and publications, our personal analysis and opinions, and contents provided by third parties, which are intended for educational and research purposes only. It does not constitute, and should not be read as, any recommendation or advice to take any action whatsoever, including to make any investment or buy any product. When making any financial ...

J Studios/DigitalVision via Getty Images Investment Thesis In my search to find the best companies, I evaluate publicly traded companies in a wide variety of sectors and industries. Previously I have evaluated consumer discretionary companies like restaurants and cruise lines, however, with experience in cell and molecular biology, I can apply this knowledge to evaluate companies in biotech to see if they warrant further investment. Based on the fundamental analysis below, Halozyme Therapeutics, Inc. (NASDA ...

12 August 2024 | 2:31AM EDT 2131d4eaf4cb4d50b1d51c8af07b64b4 Halozyme Therapeutics Inc. (HALO): What is the potential upside on pending launches, new partnerships? HALO's revenue and cash flows are primarily (and increasingly) driven by royalty revenues on Enhanze partnered products, which offer predictable and high margin growth, consistent with management guidance through 2028. However, we frequently field questions on where there is potential discovery value on this platform, thus we highlight two avenue ...

Halozyme Therapeutics, Inc. (HALO) reported second-quarter 2024 adjusted earnings of 91 cents per share, which surpassed the Zacks Consensus Estimate of 78 cents. The company had recorded earnings of 74 cents per share in the year-ago period. Total revenues increased almost 5% year over year to $231.4 million in the second quarter. Revenues surpassed the Zacks Consensus Estimate of $211 million. The top line was driven by higher royalty payments from Roche (RHHBY) for Phesgo and higher sales of proprietary ...

| --- | --- | |---------------------------------------------------|-------| | | | | Halozyme Therapeutics, Inc. | | | Second Quarter 2024 Financial & Operating Results | | | NASDAQ: HALO | | | | | | August 6, 2024 | | | | | 1 Forward Looking Statements In addition to historical information, the statements set forth in this presentation include forward-looking statements including, without limitation, statements concerning the Company's expected future growth, financial performance (including the Company's 2 ...

Financial Data and Key Metrics Changes - Total revenue in Q2 2024 grew to $231 million, supporting full-year growth expectations of 13% to 22% [6][35] - Royalty revenue reached $125 million, an increase of 12% year-over-year, marking the 16th consecutive quarter of double-digit year-on-year royalty growth [6][35] - Adjusted EBITDA grew by 19% to $137 million, with non-GAAP diluted earnings per share increasing by 23% to $0.91 [6][37] Business Line Data and Key Metrics Changes - The ENHANZE IP portfolio was strengthened with a new patent granted in Europe, extending coverage to March 6, 2029 [7][8] - The approval of OCREVUS subcutaneous and VYVGART Hytrulo expanded ENHANZE's reach into neurology and autoimmune diseases [9][10] - Sales of DARZALEX in Q2 were $2.9 billion, a 21.3% increase year-over-year, driven by share gains across therapy lines [15][16] Market Data and Key Metrics Changes - OCREVUS subcutaneous has a PDUFA action date of September 13, 2024, with the brand maintaining a 26% global patient share [25][26] - Phesgo sales increased by 60% to almost CHF800 million in the first half of 2024, with Roche expecting global conversion to reach 50% by 2026 [17] - Nivolumab IV sales grew 16% to $2.4 billion in Q2, with expectations for significant conversion to subcutaneous formulations [27] Company Strategy and Development Direction - The company aims to achieve $1 billion in royalty revenue by 2027, driven by strong performance from Wave 2 products and new royalty streams from Wave 3 products [14] - The focus remains on expanding ENHANZE technology into new treatment areas, with ongoing discussions for new partnerships [41][50] - The company is actively seeking M&A opportunities, particularly in drug delivery and licensing models that align with its high-margin business profile [74] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in achieving financial targets, citing a strong pipeline of launches and growing awareness of subcutaneous technology [39] - The company anticipates continued growth in royalty revenue, particularly in the second half of the year, following the reinstatement of full royalty rates [38][70] - Management noted that external factors like election uncertainty have not impacted partnership discussions [54] Other Important Information - The company completed a $250 million ASR, bringing total shareholder returns via share repurchases to $1.3 billion over five years [34] - Cash and marketable securities increased to $529 million as of June 30, 2024, reflecting strong operational cash generation [35] Q&A Session Summary Question: Overview of new partnership activities - Management is confident in securing additional deals, primarily focused on ENHANZE technology, with a mix of established and early-stage products [41] Question: Drivers of higher-than-expected API sales - API sales were higher due to partner demand shifts, with expectations for flat sales in Q3 [42][43] Question: Potential partnerships in the myostatin pathway - The company is interested in targeting obesity and muscle loss areas and is actively reaching out to relevant companies [46] Question: Updates on undisclosed Roche and Chugai products - Details on these products remain confidential, and no near-term disclosure plans have been indicated by partners [49] Question: Impact of PALOMA 3 results on partnership discussions - The PALOMA 3 results have generated interest, particularly in areas like nucleic acids and mRNA, but further data is needed [51] Question: Expectations for new ENHANZE deals - Management remains optimistic about signing new deals this year, with ongoing discussions with around 10 companies [70][71]

For the quarter ended June 2024, Halozyme Therapeutics (HALO) reported revenue of $231.35 million, up 4.7% over the same period last year. EPS came in at $0.91, compared to $0.74 in the year-ago quarter. The reported revenue compares to the Zacks Consensus Estimate of $210.92 million, representing a surprise of +9.69%. The company delivered an EPS surprise of +16.67%, with the consensus EPS estimate being $0.78. While investors scrutinize revenue and earnings changes year-over-year and how they compare with ...